Cancer Immune Monitoring and Analysis Centers (CIMACs) will serve as the main units of the Network for correlative studies in clinical trials involving cancer immunotherapy, functioning as platforms for deep molecular characterization of tumor and immune profiling using state-of-the-art analytically-validated and standardized platforms. Each CIMAC will encompass a multidisciplinary group with basic, translational, clinical, and computational research expertise, that will together enable significant advancement of translational research efforts.

There are four Cancer Immune Monitoring and Analysis Centers (CIMACs) within the network, each contributing a level of experimental and analytical expertise to the mission: Stanford Cancer Institute; Precision Immunology Institute and the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, New York; University of Texas MD Anderson Cancer Center in Houston; and Dana-Farber Cancer Institute in Boston.

Each CIMAC will be in a primary alignment with 1-2 trial networks, but may also work outside their primary alignment in order to extend their unique assay capabilities to the entire network. Primary trial network partners will be ETCTN, CITN, Ped-CITN, NCTN, ABTC, and PBTC. The CIMACS will also work collaboratively with the CIDC to enable data standardization and the development of uniform analysis pipelines across the studies within the Network and with public databases outside the Network.